M Raymond V Finlay

List of Publications by Year
in descending order

17 papers	3,000 citations	567281 15 h-index	940533 16 g-index
17 all docs	17 docs citations	17 times ranked	4414 citing authors

#	Article	IF	Citations
1	AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer. Cancer Discovery, 2014, 4, 1046-1061.	9.4	1,655
2	Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor. Journal of Medicinal Chemistry, 2014, 57, 8249-8267.	6.4	454
3	Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR). Journal of Medicinal Chemistry, 2013, 56, 7025-7048.	6.4	201
4	AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. Nature Communications, 2019, 10, 5065.	12.8	195
5	Preclinical Comparison of the Bloodâ€“brain barrier Permeability of Osimertinib with Other EGFR TKIs. Clinical Cancer Research, 2021, 27, 189-201.	7.0	106
6	Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Molecular Cancer Therapeutics, 2018, 17, 885-896.	4.1	80
7	The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor. Journal of Medicinal Chemistry, 2020, 63, 3461-3471.	6.4	47
8	Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy. Journal of Clinical Investigation, 2019, 130, 258-271.	8.2	45
9	Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5352-5359.	2.2	37
10	Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 6486-6489.	2.2	34
11	Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4442-4446.	2.2	32
12	Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5487-5492.	2.2	28
13	Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4163-4168.	2.2	28
14	Discovery of AZD3147: A Potent, Selective Dual Inhibitor of mTORC1 and mTORC2. Journal of Medicinal Chemistry, 2015, 58, 2326-2349.	6.4	24
15	Discovery of a Thiadiazoleâ€“Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models. Journal of Medicinal Chemistry, 2019, 62, 6540-6560.	6.4	21
16	Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance. Journal of Medicinal Chemistry, 2021, 64, 13704-13718.	6.4	13
17	Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8H-purin-8-one Inhibitors of DNA-PK. ACS Medicinal Chemistry Letters, 2022, 13, 1295-1301.	2.8	0